Clinical Trials Logo

Clinical Trial Summary

This is a prospective, parallel group, randomized, investigator-blinded pilot study. Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a weight-based dose per label or Centrum Adult Multivitamin to take by mouth daily. The study is comprised of 5 visits: screening, baseline, week 4, week 8, and week 12. Investigators will perform rosacea IGA (Investigator Global Assessment,) inflammatory lesion count, record adverse events and con meds, and ask each subject to complete a DLQI (Dermatology Life Quality Index.)

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04555525
Study type Interventional
Source Derm Research, PLLC
Status Completed
Phase Phase 4
Start date April 15, 2019
Completion date October 1, 2020

See also
  Status Clinical Trial Phase
Completed NCT03064438 - Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea Phase 2
Active, not recruiting NCT05108025 - DMT310-005 Topical in the Treatment of Acne Rosacea Phase 2
Completed NCT02270411 - Inflammatory Cells From Various Pathologies
Completed NCT02147691 - Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study Phase 4
Recruiting NCT04214483 - A Pilot Study to Explore the Role of Gut Flora in Acne
Completed NCT00041977 - Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea Phase 3
Completed NCT03003104 - DMT210 Topical Gel in the Treatment of Acne Rosacea Phase 2
Completed NCT00580723 - Effects of PRK 124 Lotion in Acne Rosacea Phase 1/Phase 2